Constraining specificity in the N‐domain of tissue inhibitor of metalloproteinases‐1; gelatinase‐selective inhibitors
- 1 September 2007
- journal article
- Published by Wiley in Protein Science
- Vol. 16 (9) , 1905-1913
- https://doi.org/10.1110/ps.072978507
Abstract
The tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of the matrix metalloproteinases (MMPs). Since unregulated MMP activities are linked to arthritis, cancer, and atherosclerosis, TIMP variants that are selective inhibitors of disease-related MMPs have potential therapeutic value. The structures of TIMP/MMP complexes reveal that most interactions with the MMP involve the N-terminal pentapeptide of TIMP and the C-D beta-strand connector which occupy the primed and unprimed regions of the active site. The loop between beta-strands A and B forms a secondary interaction site for some MMPs, ranging from multiple contacts in the TIMP-2/membrane type-1 (MT1)-MMP complex to none in the TIMP-1/MMP-1 complex. TIMP-1 and its inhibitory domain, N-TIMP-1, are weak inhibitors of MT1-MMP; inhibition is not improved by grafting the longer AB loop from TIMP-2 into N-TIMP-1, but this change impairs binding to MMP-3 and MMP-7. Mutational studies with N-TIMP-1 suggest that its weak inhibition of MT1-MMP, as compared to other N-TIMPs, arises from multiple (>3) sequence differences in the interaction site. Substitutions for Thr2 of N-TIMP-1 strongly influence MMP selectivity; Arg and Gly, that generally reduce MMP affinity, have less effect on binding to MMP-9. When the Arg mutation is added to the N-TIMP-1(AB2) mutant, it produces a gelatinase-specific inhibitor with Ki values of 2.8 and 0.4 nM for MMP-2 and -9, respectively. Interestingly, the Gly mutant has a Ki of 2.1 nM for MMP-9 and >40 muM for MMP-2, indicating that engineered TIMPs can discriminate between MMPs in the same subfamily.Keywords
This publication has 46 references indexed in Scilit:
- Matrix metalloproteinases and the regulation of tissue remodellingNature Reviews Molecular Cell Biology, 2007
- Reactive Site Mutations in Tissue Inhibitor of Metalloproteinase-3 Disrupt Inhibition of Matrix Metalloproteinases but Not Tumor Necrosis Factor-α-converting EnzymeJournal of Biological Chemistry, 2005
- Crystal Structure of the Catalytic Domain of MMP-16/MT3-MMP: Characterization of MT-MMP Specific FeaturesJournal of Molecular Biology, 2004
- Unveiling the Surface Epitopes That Render Tissue Inhibitor of Metalloproteinase-1 Inactive against Membrane Type 1-Matrix MetalloproteinaseJournal of Biological Chemistry, 2003
- Crystal Structure of Human MMP9 in Complex with a Reverse Hydroxamate InhibitorJournal of Molecular Biology, 2002
- Compromise and accommodation in ecotin, a dimeric macromolecular inhibitor of serine proteases 1 1Edited by R. HuberJournal of Molecular Biology, 2000
- Structure of Human Pro-Matrix Metalloproteinase-2: Activation Mechanism RevealedScience, 1999
- Folding and characterization of the amino‐terminal domain of human tissue inhibitor of metalloproteinases‐1 (TIMP‐1) expressed at high yield in E. coliFEBS Letters, 1996
- Crystal structures of matrilysin-inhibitor complexesBiochemistry, 1995
- Site-directed mutagenesis by overlap extension using the polymerase chain reactionGene, 1989